Edition:
United States

Agenus Inc (AGEN.O)

AGEN.O on Consolidated Issue listed on NASDAQ Capital Market

4.47USD
19 Oct 2017
Change (% chg)

-- (--)
Prev Close
$4.47
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,107,637
52-wk High
$6.09
52-wk Low
$3.20

Chart for

About

Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast... (more)

Overall

Beta: 2.16
Market Cap(Mil.): $388.89
Shares Outstanding(Mil.): 87.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 90.61 17.08
EPS (TTM): -- -- --
ROI: -- 2.45 11.26
ROE: -- 3.37 15.09

BRIEF-Agenus files for mixed shelf of up to $250 million

* Agenus Inc files for mixed shelf of up to $250 million – SEC filing‍​ Source text - (http://bit.ly/2yzul1n) Further company coverage:

Oct 18 2017

'Impressed' FDA panel unanimously recommends GSK shingles vaccine

A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.

Sep 13 2017

UPDATE 2-'Impressed' FDA panel unanimously recommends GSK shingles vaccine

Sept 13 A U.S. Food and Drug Administration advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline's Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.

Sep 13 2017

BRIEF-Agenus Inc Q2 loss per share $0.32

* Agenus reports second quarter 2017 financial results and provides corporate update

Aug 03 2017

BRIEF-AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

* AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

Jun 05 2017

BRIEF-Agenus Q1 loss per share $0.18

* Agenus reports first quarter 2017 financial results and provides corporate update

May 04 2017

BRIEF-Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

* Phase 1/2 clinical trial of Agenus' anti-PD-1 antibody begins

Apr 20 2017

Earnings vs. Estimates